OncoMatch/Clinical Trials/NCT07044635
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
Is NCT07044635 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for oropharyngeal squamous cell carcinoma.
The goal of this study is to evaluate if a shorter course of therapy can improve the quality of life in patients receiving radiation therapy after trans-oral robotic surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A p16 positivity
p16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor
Required: HPV positivity by in situ hybridization
p16 positivity or HPV positivity by in situ hybridization on pathological sampling of lymph node or primary oropharyngeal tumor
Required: HPV TTMV-HPV DNA test
Pre-operative TTMV-HPV DNA test collected or is planned to be collected
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
History of prior mucosal head and neck cancer treated with radiation therapy
Cannot have received: systemic anti-cancer therapy
Exception: ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter
Prior systemic anti-cancer therapy or any investigational therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute/University of Utah · Salt Lake City, Utah
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07044635 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy, systemic anti-cancer therapy disqualifies patients from enrollment.
Does this trial require CDKN2A?
Yes, CDKN2A p16 positivity is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV positivity by in situ hybridization is a required biomarker for enrollment.
Does this trial require HPV?
Yes, HPV TTMV-HPV DNA test is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages